CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体 (CAR) T 细胞疗法的神经毒性并发症
英文原题：Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy.
查看英文原题
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法改变了血液系统恶性肿瘤治疗，并在实体瘤、神经系统自身免疫病和风湿性自身免疫病的早期试验中显示疗效。然而，部分患者接受 CAR-T 后会出现神经毒性综合征，包括免疫效应细胞相关神经毒性综合征，以及近期描述的治疗期间新发运动和神经认知不良事件、肿瘤炎症相关神经毒性。这些神经毒性综合征仍未得到充分理解，且与显著发病率和死亡率相关。由神经科、血液科和肿瘤科医生组成的多学科团队，对于诊断和管理 CAR-T 神经毒性至关重要。随着 CAR-T 应用扩展、适应证增多以及新型神经毒性综合征出现，这种多学科方法将日益重要。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and rheumatological autoimmune diseases.
However, CAR-T is complicated in some patients by neurotoxicity syndromes including immune-effector cell-associated neurotoxicity syndrome, and the more recently described movement and neurocognitive treatment-emergent adverse events, and tumour inflammation-associated neurotoxicity. These neurotoxic syndromes remain poorly understood and are associated with significant morbidity and mortality.
A multidisciplinary approach, including neurologists, haematologists and oncologists, is critical for the diagnosis and management of CAR-T neurotoxicity. This approach will be of increasing importance as the use of CAR-T expands, its applications increase and as novel neurotoxic syndromes emerge.
论文信息
- 作者
- Vonberg FW、Malik I、O'Reilly M、Hyare H、Carr AS、Roddie C
- 单位
- National Hospital for Neurology and Neurosurgery, London, UK frederick.vonberg@nhs.net.United Kingdom
- 文献类型
- 综述
- 期刊
- Journal of neurology, neurosurgery, and psychiatry2025 Jun 12
- 原文标识
- PubMed 40185628 · DOI 10.1136/jnnp-2024-333924